At the time of this work, no small molecule inhibitors were available in the public domain to validate STK17B as a cancer immunotherapy target, nor assays to enable investigation of STK17B, such as biochemical and cellular target engagement assays, or pharmacokinetic (PK)/pharmacodynamic (PD) models. This evidence concerns the gene STK17B and cancer.